Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 9Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 2Peripheral Nervous System Diseases 1Anemia 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × Epoetin Alfa × Clear all
NCT00267007 2014-06-04

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Terminated
32 enrolled 9 charts

Neoplasms, Peripheral Nervous System Diseases

NCT00386152 2013-07-19

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Terminated
235 enrolled 13 charts
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡